Metronomic low-dose gemcitabine, mitomycin C, and thalidomide for advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label, single-site phase II study will assess safety and preliminary effectiveness of metronomic low-dose gemcitabine and mitomycin C given intravenously, plus oral thalidomide, in about 40–60 patients with pathologically confirmed advanced solid tumors. Patients receive gemcitabine on days 1, 8, and 15; mitomycin C every six weeks; and thalidomide daily for 15 days, with imaging every 6 weeks for 6 months and then every 12 weeks until progression or unacceptable toxicity up to one year. Response and progression will be monitored by RECIST v1.1, along with safety labs and adverse event reporting. The study aims to determine whether this metronomic regimen can achieve disease control with manageable toxicity in a population with limited options.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or Female ≥ 18 years of age
2. Pathologically confirmed diagnosis of locally advanced or metastatic solid tumor
3. Previously treated participants
4. Measurable disease by RECIST v1.1
5. ECOG performance status ≤ 1
6. Life expectancy of at least 3 months
7. Acceptable liver function: Bilirubin ≤ 1.5 times upper limit of normal (ULN; except subjects with Gilbert Syndrome who must have a total bilirubin level \< 3.0 ULN); AST (SGOT), ALT (SGPT) and alkaline phosphatase ≤ 3 x ULN (\< 5 x ULN if liver metastases); Acceptable renal function: Creatinine \< 1.5 times ULN
8. Acceptable hematologic status (without hematologic support e.g. growth factors or transfusion within 21 days of first dose of study agents): ANC ≥ 1500 cells/μL; Platelet count ≥ 100,000/μL; Hemoglobin ≥ 9.0 g/dL; Normal PT, PTT, INR
9. All women of childbearing potential must have a negative pregnancy test and all subjects must agree to use highly effective means of contraception (surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through 5 months for women and 7 months for men after the last dose.
10. Females of reproductive potential must have 2 negative pregnancy tests before initiating THALOMID. The first test should be performed within 10-14 days, and the second test within 24 hours prior to prescribing THALOMID. Once treatment has started and during dose interruptions, pregnancy testing for females of reproductive potential should occur weekly during the first 4 weeks of use, then pregnancy testing should be repeated every 4 weeks in females with regular menstrual cycles. If menstrual cycles are irregular, the pregnancy testing should occur every 2 weeks. Pregnancy testing and counseling should be performed if a patient misses her period or if there is any abnormality in her menstrual bleeding. THALOMIDE treatment must be discontinued during this evaluation.
11. Ability to understand the purposes and risks of the study and has signed and dated a written informed consent form approved by the principal investigator's IRB/Ethics Committee
12. Willingness to comply with all study procedures and availability for the duration of the study.

Exclusion Criteria:

1. Subjects with untreated CNS metastases. Subjects are eligible if CNS metastases have been adequately treated and have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to treatment initiation. In addition, subjects must be either off corticosteroids, or on a stable or decreasing dose of \<10 mg daily prednisone (or equivalent) for at least 2 weeks prior to treatment initiation.
2. Subjects with carcinomatous meningitis
3. Subjects who participated in an investigational drug or device study within 14 days prior to study entry
4. Subjects who had chemotherapy within 14 days prior to study entry
5. Females who are pregnant or breast-feeding
6. Unwillingness or inability to comply with the study protocol for any reason
7. Evidence of severe or uncontrolled systemic disease or any other concurrent condition, including psychiatric, which in the principal investigator's opinion makes it undesirable for the participant to participate in the trial or which would jeopardize compliance with the trial
8. Any positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection
9. Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).

Where it's running

• Sarcoma Oncology Research Center / Cancer Center of Southern California
  Santa Monica, California, United States Recruiting

Study contacts

• Principal investigator: Neal S. Chawla, MD — Sarcoma Oncology Research Center, LLC
• Study coordinator: Erlinda M. Gordon, MD
• Email: egordon@sarcomaoncology.com
• Phone: 3105529999

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Urine samples from adults with solid cancers to explore chemistry linked to nearing end of life

  This study tests urine chemistry in adults with solid tumors to see if it reflects how close a patient is to death.

  Recruiting The Clatterbridge Cancer Centre NHS Foundation Trust · Liverpool, Merseyside · NCT07848997

• Tempus Open Link registry for cancer patients using Olivia platform

  This registry tests whether Olivia can securely enroll cancer patients and combine their health data from EHRs and patient-reported outcomes to build a large, de-identified dataset.

  Recruiting Tempus AI · Chicago, Illinois · NCT07756034

• Imaging with 89Zr-DFO-YS5 to detect cancer

  This study tests a new PET radiotracer, 89Zr-DFO-YS5, to see if it can show cancer sites in adults with nerve sheath tumors, bladder cancer, or other solid tumors.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT07664397

• JL19001 Injection Alone or with Standard Therapy in Advanced Solid Tumors or Relapsed/Refractory B-Cell NHL

  This phase 1 trial tests JL19001 by itself or with standard treatment to see if it is safe and tolerable in adults with advanced solid tumors or relapsed/refractory B-cell non-Hodgkin lymphoma.

  Recruiting Phase 1 Jecho Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality · NCT07603479

• Phase 1 dose-escalation and expansion test of IUAb190708 for advanced or recurrent solid tumors

  This trial tests IUAb190708, a new cytotoxic anti–PD‑L1 antibody given by IV, to see if it is safe and can kill tumors in adults with advanced or recurrent solid cancers.

  Recruiting at 6 sites Phase 1 ImmunoUrchin · Fuzhou, Fujian and 5 other locations · NCT07584954

• IL-22BP mRNA peptide therapy for advanced solid tumors

  A phase 1 study tests a new peptide-delivered IL-22BP mRNA treatment to see if it is safe and if it has any early signs of shrinking or stopping advanced solid tumors in adults.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07583654

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.